Zebrafish for modeling stroke and their applicability for drug discovery and development. (3rd June 2022)

• Record Type: Journal Article
• Authors: Crilly, Siobhan; McMahon, Emily; Kasher, Paul R.
• Is Part Of: Expert opinion on drug discovery. Volume 17:Number 6(2022)
• Page Start: 559
• Page End: 568
• Publication Date: 2022-06-03
• Subjects: Zebrafish -- ischemic stroke -- hemorrhagic stroke -- pre-clinical modeling -- drug screening; 615.1
• DOI: 10.1080/17460441.2022.2072828
• Languages: English
• ISSNs: 1746-0441

Abstract

ABSTRACT: Introduction: The global health burden of stroke is significant and few therapeutic treatment options currently exist for patients. Pre-clinical research relies heavily on rodent stroke models but the limitations associated with using these systems alone has meant translation of drug compounds to the clinic has not been greatly successful to date. Zebrafish disease modeling offers a potentially complementary platform for pre-clinical compound screening to aid the drug discovery process for translational stroke research. Areas covered: In this review, the authors introduce stroke and describe the issues associated with the current pre-clinical drug development pipeline and the advantages that zebrafish disease modeling can offer. Existing zebrafish models of ischemic and hemorrhagic stroke are reviewed. Examples of how zebrafish models have been utilized for drug discovery in other disease disciplines are also discussed. Expert opinion: Zebrafish disease modeling holds the capacity and potential to significantly enhance the stroke drug development pipeline. However, for this system to be more widely accepted and incorporated into translational stroke research, continued improvement of the existing zebrafish stroke models, as well as focussed collaboration between zebrafish and stroke researchers, is essential.